Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals, Inc.

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies.

Actinium Pharmaceuticals, Inc. | 13,072 followers on LinkedIn. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT

Vice President, Patent and Legal Counsel at Actinium Pharmaceuticals, Inc.

Paul Diamond

Biotech Executive | Finance & Operations | Biotech Growth Specialist | Vice President, Finance @ Actinium Pharmaceuticals

Steve Dressel

Gary Siegel

Chief Business Officer

Lynn Bodarky

Actinium Pharmaceuticals (NYSE: ATNM) Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors. Read the press release here: https://bit.ly/4eftEdy

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology. Read the press release here: https://bit.ly/3MOAuf4 #AML #Radiotherapies

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. Read the press release here: https://bit.ly/3Ad5jXP

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted #Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications. Read the press release here: https://bit.ly/3A2I02C #CARTcelltherapy #CellTherapy

Actinium (NYSE: ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for #SickleCellDisease Patients Undergoing #BoneMarrowTransplant in Collaboration with Columbia University. Read the press release here: https://bit.ly/3A8BnvC #BMT

Actinium Pharmaceuticals (NYSE: ATNM) to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US. Read the press release here: https://bit.ly/3YfmQZ9 #Radiotherapy

#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX

#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3

Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ

Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue								1.14M -	1.03M 9.97%	81K 92.14%
cost of revenue
gross profit								1.14M -	1.03M 9.97%	81K 92.14%
selling and marketing expenses
general and administrative expenses	10.18M -	11.46M 12.67%	9.27M 19.15%	9.16M 1.22%	6.73M 26.46%	5.52M 17.98%	6.31M 14.24%	8.08M 28.04%	12.00M 48.56%	13.33M 11.10%
selling general and administrative expenses	10.18M -	11.46M 12.67%	9.27M 19.15%	9.16M 1.22%	6.73M 26.46%	5.52M 17.98%	6.31M 14.24%	8.08M 28.04%	12.00M 48.56%	13.33M 11.10%
research and development expenses	12.27M -	13.31M 8.51%	17.50M 31.47%	17.70M 1.13%	17.09M 3.42%	16.55M 3.19%	16.09M 2.81%	18.03M 12.10%	23.14M 28.31%	38.67M 67.15%
other expenses	37.91K -	53.47K 41.04%	77.52K 45.00%	55.94K 27.84%
cost and expenses	22.48M -	24.83M 10.45%	26.85M 8.13%	26.91M 0.24%	23.83M 11.46%	22.07M 7.37%	22.39M 1.46%	26.11M 16.59%	35.13M 34.57%	52.00M 48.01%
operating expenses	22.48M -	24.83M 10.45%	26.85M 8.13%	26.91M 0.24%	23.83M 11.46%	22.07M 7.37%	22.39M 1.46%	26.11M 16.59%	35.13M 34.57%	52.00M 48.01%
interest expense	866 -	7.87K 808.55%	5.01K 36.36%	5.43K 8.45%	173.36K 3,092.62%				-1.09M -
ebitda	-22.44M -	-24.78M 10.40%	-26.77M 8.05%	-27.16M 1.45%	-23.78M 12.45%	-21.65M 8.94%	-21.95M 1.36%	-24.44M 11.36%	-33.41M 36.68%	-51.92M 55.43%
operating income	-22.48M -	-24.83M 10.45%	-26.85M 8.13%	-26.91M 0.24%	-23.83M 11.46%	-22.07M 7.37%	-22.39M 1.46%	-24.96M 11.48%	-34.10M 36.61%	-51.92M 52.24%
depreciation and amortization	37.91K -	53.47K 41.04%	77.52K 45.00%	55.94K 27.84%	50.72K 9.33%	420.09K 728.23%	447K 6.41%	524K 17.23%	699K 33.40%
total other income expenses net	-2.21M -	3.81M 272.81%	2.53M 33.62%	304.12K 87.98%	173.36K 43.00%	172.39K 0.56%	178K 3.25%	190K 6.74%	1.09M 472.11%	3.10M 185.37%
income before tax	-24.69M -	-21.03M 14.83%	-24.32M 15.68%	-26.60M 9.37%	-23.65M 11.08%	-21.90M 7.42%	-22.21M 1.44%	-24.77M 11.52%	-33.02M 33.27%	-48.82M 47.86%
income tax expense	866 -	7.87K 808.55%	5.01K 36.36%	-309.55K 6,282.40%	173.36K 156.00%	-172.39K 199.44%	-178K 3.25%	-190K 6.74%	-1.09M 472.11%
net income	-24.69M -	-21.03M 14.83%	-24.32M 15.68%	-26.60M 9.37%	-23.65M 11.08%	-21.73M 8.15%	-22.04M 1.43%	-24.58M 11.56%	-31.93M 29.88%	-48.82M 52.89%
weighted average shs out	912.12K -	1.27M 39.45%	1.62M 27.01%	2.22M 37.73%	3.53M 58.87%	4.98M 40.77%	12.13M 143.87%	20.57M 69.51%	24.14M 17.37%	266.04K 98.90%
weighted average shs out dil	912.12K -	1.27M 39.45%	1.62M 27.01%	2.22M 37.73%	3.53M 58.87%	4.98M 40.77%	12.13M 143.87%	20.57M 69.51%	24.14M 17.37%	266.04K 98.90%
eps	-27.07 -	-16.53 38.94%	-15.06 8.89%	-11.96 20.58%	-6.69 44.06%	-4.37 34.68%	-1.82 58.35%	-1.20 34.07%	-1.32 10.00%	-183.50 13,801.52%
epsdiluted	-27.07 -	-16.53 38.94%	-15.06 8.89%	-11.96 20.58%	-6.69 44.06%	-4.37 34.68%	-1.82 58.35%	-1.20 34.07%	-1.32 10.00%	-183.50 13,801.52%

COM:ACTINIUMPHARMA

Actinium Pharmaceuticals, Inc.

Last Close

1.47

22/11 21:00

Market Cap

210.57M

Beta: -

Volume Today

222.68K

Avg: -

Preview